Considering the beneficial effects of GcgR antagonists on glycaemia [66–68], it would seem counterintuitive to employ agonism in a therapy for obesity and, certainly, diabetes. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.